Other Non-Current Liabilities

12 Months Ended

Dec. 31, 2020

Included within other non-current liabilities at December 31, 2020 is $2.3 million (December 31, 2019: $2.4 million) relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.

The contingent liability was remeasured in the third quarter of 2020 to reflect a change in the timing of expected payments following the Company's decision not to advance the DDS-01 series of antibiotics and to cease work on the gonorrhea program. The gain on remeasurement of the liability is included within other income (expense) in the Consolidated Statement of Operations and Comprehensive (Loss) Income. The table below describes the value of the assumed contingent liabilities as of December 31, 2020, of $2.3 million compared to what the total value would be following the presented variations to the underlying assumptions in the model:


			December 31, 2020
Estimated assumed contingent liabilities			(In thousands)
1% lower discount rate			2,416
1% higher discount rate			2,129
10% lower probability of success			1,864
10% higher probability of success			2,630